Physician profile
Nicole Vecchi
NPI 1407882863
$2,906.33
in general payments reported to CMS, 2019-2025
18 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $42.17 · 2021: $333 · 2022: $313 · 2023: $12.85 · 2024: $46.84 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.53 | 2019 | |
| Boston Scientific Corporation | $421.33 | 2021-2022 | |
| Novo Nordisk INC | $370.25 | 2020-2025 | Ozempic, Wegovy |
| Amgen INC. | $288.38 | 2019-2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $202.47 | 2021-2025 | Breztri |
| Glaxosmithkline, LLC. | $159.94 | 2022-2024 | Trelegy Ellipta |
| Dexcom, INC. | $144.70 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Lilly USA, LLC | $124.99 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $121.08 | 2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $117.84 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $106.08 | 2019 | |
| Merck Sharp & Dohme LLC | $94.71 | 2025 | Capvaxive |
| Sanofi Pasteur INC. | $38.14 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $22.39 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $20.67 | 2024 | Flector, Tirosint, Licart |
| Abbvie INC. | $14.70 | 2022 | |
| Genentech USA, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Vecchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.